The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native brings considerable expertise acquired from previous managerial roles in internationally active pharmaceutical companies, as well as leadership experience and a strong international network. “The addition of Hans Peter Hasler to our Supervisory Board highlights our focus on expansion,” explains Dr Rudolf Widmann, CEO of AOP Orphan. “With his decades of expertise as a manager of and independent consultant for renowned, globally active pharmaceutical companies, he is a valuable addition to AOP Orphan.”
After a period of around seven years in the Wyeth group, where Hans Peter Hasler held various managerial positions in Zug and Münster, among others, he worked for the US biotech company Biogen Idec, Inc. from 2001 to 2009. He ultimately managed the company as Chief Operating Officer in Boston, being responsible for global business operations, the commercial development and medical affairs of the company with 1,500 employees and a turnover of USD 4.1 billion. Most recently, Hans Peter Hasler was the Chief Operating Officer for the Irish-American biotech company Elan Corporation, plc. in Dublin, where he shared responsibility for the sale of Tysabri to Biogen Idec, Inc. for 3.4 billion Irish Pounds, among other things.
Mr Hasler was also active as an independent consultant for pharmaceutical and biotech companies with HPH Management GmbH, which he founded. Moreover, he is currently President of the Board of Directors at HBM Healthcare Investments AG in Zug and Chairman of the Board of Management of MIAC AG (Medical Imaging Analysis Center), a non-profit spin-off from the Basel university hospital.